Does anyone know about Capivasertib

[Ian99]

Anyone aware of Capivasertib (truqap ) ? Approved by FDA. Am considering a trial involving Docetaxel and Capivasertib. Am interested in any feedback on this drug, which has not yet been approved here. Thanks.

[GP24]

The combination was tested in this trial and extended overall survival: pubmed.ncbi.nlm.nih.gov/356...

[Ian99 in reply to GP24]

Thanks

[Tall_Allen]

Here's what I have:

sciencedirect.com/science/a...

It is thought to be particularly effective in men who have a genomic issue called "PTEN loss," and there are a few of trials for that:

clinicaltrials.gov/study/NC...

clinicaltrials.gov/study/NC...

Those are for men who are still hormone-sensitive, but there are some trials for men with PTEN-loss who are castration-resistant using biosimilar drugs:

clinicaltrials.gov/study/NC...

classic.clinicaltrials.gov/...

A biosimilar drug, ipatasertib, had mixed results in a trial to men who are castration-resistant with PTEN-loss:

thelancet.com/journals/lanc...

However, it was quite toxic:

clinical-genitourinary-canc...

Capivasertib may be less toxic and has been FDA-approved for women with some types of breat cancer.

[j-o-h-n]

On Cousin Google:

Phosphatidylinositol-3-kinase (PI3K)/Akt (PI3K/AKT) pathway is one of the most commonly altered pathways in breast cancer.•

Capivasertib (AZD5363) is a highly potent Akt kinase inhibitor with activity against the three isoforms AKT1, AKT2, and AKT3.•

Preclinical studies demonstrated efficacy of capivasertib either alone or in combination with anti-HER2 agents, chemotherapy and endocrine treatment.•

Dose-limiting toxicities include hyperglycemia (20–24%), diarrhea (14–17%) and maculopapular rash (11–16%).•

Capivasertib increased susceptibility to paclitaxel (PAKT, BEECH), fulvestrant (NCT01226316, FAKTION) or Olaparib (ComPAKT).

Good Luck, Good Health and Good Humor.

j-o-h-n